The safety and feasibility of CRISPR/Cas 9 gene editing technology by knocking out PD-1 in T cells are proved in a clinical study treating NSCLC by Lu in 2020, but the therapeutic efficacy should be improved in the next clinic experiments (Lu et al., 2020). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.